Looking Ahead to 2012 with Matthew Herper, Forbes
Submitted by Theral Timpson on Tue, 12/27/2011 - 17:05Podcast Sponsor: As the year takes off, we thank all our sponsors who have made mendelspod possible.
Affymetrix, Biotix, Epitomics, IDT, Ingenuity, Lab Roots, Laboratory Products Sales, Mo Bio, Science Exchange, Singulex, Traitwise
Guest:
Matthew Herper, Science and Medicine Reporter, Forbes and Forbes.com Bio and Contact Info
Listen (4:17) More super expensive drugs
Listen (5:48) New genetic technologies to face the valley of death
Listen (1:15) Health IT will stall
Listen (4:15) Winning companies of 2011
Listen (3:09) Are we seeing innovation in big pharma model?
Listen (1:38) VC funding
Listen (6:56) Cancer's moment of promise and chaos
Listen (6:00) I like telling stories about science
Listen (4:38) Bill Gates changes the world again
Listen (6:09) Will 2012 political environment be good for life science?
Noted life science reporter, Matthew Herper, from Forbes looks into his crystal ball. Join us as we discuss important trends going into 2012 with a look back at those companies who did well in 2011. In November, Herper wrote a cover article for Forbes, "With Vaccines, Bill Gates Changes the World Again." Herper shares thoughts on his two interviews with Gates, commenting on the potential for the vaccine industry. Herper has an impressive perspective on the commercial side of the industry; what's having practical financial success, and what isn't.
NOTE: Matt spends some time here talking about Dendreon and the disappointing sales of their cancer drug Provenge. Shortly after our interview, Dendreon announced 4th quarter sales which beat analysts' expectations and boosted their stock immediately by 40%.
